TGFB1 and neoplasm: Indeed, one possible mechanism of anti-CTLA4 antibody therapy is the depletion of immunosuppressive TGF-β-producing Treg cells (203), thus facilitating the costimulation and expansion of tumor-specific CTL with improved clinical benefit (204, 205).